Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Entrada Therapeutics Q4 GAAP EPS $(0.29) Misses $(0.17) Estimate, Sales $41.85M Beat $23.69M Estimate

Author: Benzinga Newsdesk | March 13, 2024 07:21am

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.17) by 70.59 percent. This is a 63.29 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $41.85 million which beat the analyst consensus estimate of $23.69 million by 76.65 percent.

Posted In: TRDA